切换至 "中华医学电子期刊资源库"
高级检索
中华普外科手术学杂志(电子版)

中华普外科手术学杂志(电子版) ›› 2022, Vol. 16 ›› Issue (05) : 584 -588. doi: 10.3877/cma.j.issn.1674-3946.2022.05.030

综述

直肠癌新辅助治疗后等待观察策略的研究现状及进展
郝璐1, 袁野1, 余向南1, 李源2, 曹阳2, 陶凯雄2, 王征3, 王国斌2,†()   
  1. 1. 430022　武汉，华中科技大学同济医学院附属协和医院胃肠外科；430022　武汉，华中科技大学同济医学院附属协和医院组织工程与再生医学研究中心
    2. 430022　武汉，华中科技大学同济医学院附属协和医院胃肠外科；430022　武汉，华中科技大学同济医学院附属协和医院微创外科医学临床研究中心
    3. 430022　武汉，华中科技大学同济医学院附属协和医院胃肠外科；430022　武汉，华中科技大学同济医学院附属协和医院组织工程与再生医学研究中心；430022　武汉，华中科技大学同济医学院附属协和医院微创外科医学临床研究中心
  • 收稿日期:2021-11-29 出版日期:2022-10-26
  • 通信作者: 王国斌

Research status and progress of watch and wait strategy after neoadjuvant therapy for rectal cancer

Lu Hao1, Ye Yuan1, Xiangnan Yu1, Yuan Li2, Yang Cao2, Kaixiong Tao2, Zheng Wang3, Guobin Wang2,†()   

  1. 1. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China; Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China
    2. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China; Minimally Invasive Surgery Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China
    3. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China; Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China; Minimally Invasive Surgery Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei Province 430022, China
  • Received:2021-11-29 Published:2022-10-26
  • Corresponding author: Guobin Wang
  • Supported by:
    The Major Scientific and Technological Innovation Projects of Hubei Province(2018ACA136)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

郝璐, 袁野, 余向南, 李源, 曹阳, 陶凯雄, 王征, 王国斌. 直肠癌新辅助治疗后等待观察策略的研究现状及进展[J/OL]. 中华普外科手术学杂志(电子版), 2022, 16(05): 584-588.

Lu Hao, Ye Yuan, Xiangnan Yu, Yuan Li, Yang Cao, Kaixiong Tao, Zheng Wang, Guobin Wang. Research status and progress of watch and wait strategy after neoadjuvant therapy for rectal cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2022, 16(05): 584-588.

术前新辅助放化疗（nCRT）联合全直肠系膜切除术是目前局部进展期中低位直肠癌（LARC）的标准治疗模式。nCRT具有良好的降低肿瘤分期作用，且有15%~20%的LARC患者在nCRT后可以获得临床完全缓解（cCR）。鉴于手术潜在的术后并发症以及术后生存质量下降等考量，针对新辅助治疗后获得cCR的患者，有学者提出了等待观察策略（W&W）：即不接受手术，定期复查，从而保留器官功能，在不影响患者生存率的前提下提高生存质量。然而，W&W实施过程中出现出了以下问题：（1）应用何种新辅助治疗方案能尽可能地提高cCR率？（2）新辅助治疗后多久作为监测cCR的最佳时间？（3）cCR的正确评估及其与病理完全缓解（pCR）的关系？（4）接受W&W患者长期预后是否能达到同等手术根治效果？（5）W&W患者长期随访困难及可能的复发转移该如何处理？基于此，笔者通过对W&W开展以来的研究状况、cCR面临的争议点及研究方向等方面进行文献综述，为cCR患者的诊治提供一定的参考。

关键词: 直肠肿瘤, 新辅助治疗, 等待观察策略, 临床完全缓解

Preoperative neoadjuvant chemoradiotherapy（NCRT）combined with total mesenterectomy is the standard treatment mode for locally advanced rectal cancer（LARC）. NCRT has a good effect on reducing tumor stage，and 15% to 20% of LARC patients can obtain clinical complete remission（CCR）after NCRT. In view of the potential postoperative complications and decreased postoperative quality of life，some scholars proposed a watch and wait strategy（W&W）for patients with cCR after neoadjuvant therapy：no surgery，regular review，so as to preserve organ function and improve the quality of life without affecting the survival rate. However，the following problems emerged in the implementation of W&W：（1）Which neoadjuvant therapy can improve the cCR rate as much as possible？（2）How long is the best time to define cCR after neoadjuvant therapy？（3）The correct assessment of cCR and its relationship with pathological complete remission（pCR）？（4）Can the long-term prognosis of patients receiving W&W achieve the same effect of radical operation？（5）How to deal with the long-term follow-up difficulties and possible recurrence and metastasis of W&W patients？Based on this，the author made a literature review on the research status of W&W since its launch，the controversial points and research direction of cCR，so as to provide some reference for the diagnosis and treatment of clinical cCR patients.

Key words: Rectal neoplasms, Neoadjuvant therapy, Watch and wait, Clinical complete response
表1 直肠癌新辅助治疗后cCR患者W&W治疗策略的循证医学证据(例)
研究 时间 例 cCR(%) LR(%)
Renehan[18] 2016 259 31(12.0) 44(34)
Sanchez等[19] 2016 68 68(100.0) 6(8.8)
武爱文等[20] 2017 35 26(74.3) 5(14.3)
王林等[21] 2018 - 62（-） 15(24.2)
van der valk等[16] 2018 1009 880(87.2) 213(24.2)
Haak等[17] 2020 304 43(14.1) 5(11.6)
研究 时间 例 OS(%) DFS(%) 生存时间(年)
W&W 手术 W&W 手术
Renehan[18] 2016 259 96.0 87.0 88.0 78.0 3
Sanchez等[19] 2016 68 93.8 - 76.3 - 5
武爱文等[20] 2017 35 92.7 -

(CSS)

100.0

 - 3
王林等[21] 2018 - 88.6 - 100.0 - 3
van der valk等[16] 2018 1009 84.7 -

(DSS)

93.8

 - 5
Haak等[17] 2020 304 97.0 - 91.0 - 3
[1]
Dittrich L，Biebl M，Schmuck R，et al. Initial Experience with the Safe Implementation of Transanal Total Mesorectal Excision（TaTME）as a Standardized Procedure for Low Rectal Cancer［J］. J Clin Med，2020，10（1）：72.
[2]
Keum N，Giovannucci E. Global burden of colorectal cancer：emerging trends，risk factors and prevention strategies［J］. Nat Rev Gastroenterol Hepatol，2019，16（12）：713-732.
[3]
Ryan ÉJ，Creavin B，Sheahan K. Delivery of Personalized Care for Locally Advanced Rectal Cancer：Incorporating Pathological，Molecular Genetic，and Immunological Biomarkers Into the Multimodal Paradigm［J］. Front Oncol，2020，10：1369.
[4]
Yao Y，Xu X，Yang L，et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer［J］. Cell Stem Cell，2020，26（1）：17-26.e6.
[5]
Ryan ÉJ，O'Sullivan DP，Kelly ME，et al. Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer［J］. Br J Surg，2019，106（10）：1298-1310.
[6]
赵旭鹏，李英杰，王墨飞，等. 恒温下持续双套管冲洗引流对结直肠癌术后肠瘘患者感染控制效果的影响［J/CD］. 中华普外科手术学杂志（电子版），2019，13（6）：625-627.
[7]
Rega D，Granata V，Romano C，et al. Watch and Wait Approach for Rectal Cancer Following Neoadjuvant Treatment：The Experience of a High Volume Cancer Center［J］. Diagnostics（Basel），2021，11（8）：1507.
[8]
余向南，付达安，戴拯，等. 直肠癌前切除术吻合口漏预防及治疗［J/CD］. 中华普外科手术学杂志（电子版），2021，15（5）：587-590.
[9]
Shiraishi T，Ito M，Sasaki T，et al. Association between urinary function and resected pattern of the autonomic nerve system after transanal total mesorectal excision for rectal cancer［J］. Colorectal Dis，2021，23（2）：405-414.
[10]
Martin ST，Heneghan HM，Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer［J］. Br J Surg，2012，99（7）：918-928.
[11]
Habr-Gama A，Perez RO，Nadalin W，et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy：long-term results［J］. Ann Surg，2004，240（4）：711-717；discussion 717-718.
[12]
Habr-Gama A，Perez RO，Nadalin W，et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival［J］. J Gastrointest Surg，2005，9（1）：90-99；discussion 99-101.
[13]
Habr-Gama A，Perez RO，Proscurshim I，et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy［J］. J Gastrointest Surg，2006，10（10）：1319-1328；discussion 1328-1329.
[14]
Habr-Gama A，Perez RO，Sao Juliao GP，et al. Nonoperative approaches to rectal cancer：a critical evaluation［J］. Semin Radiat Oncol，2011，21（3）：234-239.
[15]
Habr-Gama A，Gama-Rodrigues J，Sao Juliao GP，et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation：impact of salvage therapy on local disease control［J］. Int J Radiat Oncol Biol Phys，2014，88（4）：822-828.
[16]
van der Valk MJM，Hilling DE，Bastiaannet E，et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database（IWWD）：an international multicentre registry study［J］. Lancet，2018，391（10139）：2537-2545.
[17]
Haak HE，Maas M，Lambregts DMJ，et al. Is watch and wait a safe and effective way to treat rectal cancer in older patients？［J］. Eur J Surg Oncol，2020，46（3）：358-362.
[18]
Renehan AG，Malcomson L，Emsley R，et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer（the OnCoRe project）：a propensity-score matched cohort analysis［J］. Lancet Oncol，2016，17（2）：174-183.
[19]
Sanchez Loria F，Iseas S，O'Connor JM，et al. Non-surgical management of rectal cancer. Series of 68 cases，long follow up in two leading centres in Argentina［J］. Dig Liver Dis，2016，48（11）：1372-1377.
[20]
武爱文，王林，杜长征，等. 中低位直肠癌新辅助治疗后等待观察或器官保留手术的单中心35例报告［J］. 中华胃肠外科杂志，2017，20（4）：417-424.
[21]
王林，李士杰，张晓燕，等. 中低位直肠癌新辅助治疗后临床完全缓解或近临床完全缓解的长期预后分析［J］. 中华胃肠外科杂志，2018，21（11）：1240-1248.
[22]
Huang CM，Huang CW，Ma CJ，et al. Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer［J］. World J Gastrointest Oncol，2020，12（12）：1428-1442.
[23]
Sheng X，Li S，Zhang Y，et al. One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer［J］. Front Oncol，2021，11：695726.
[24]
Wang YQ，Zhang Z. ［Role of radiotherapy in watch and wait strategy after neoadjuvant trerapy for rectal cancer］［J］. Zhonghua Wei Chang Wai Ke Za Zhi，2020，23（3）：252-257.
[25]
Francois Y，Nemoz CJ，Baulieux J，et al. Influence of the Interval Between Preoperative Radiation Therapy and Surgery on Downstaging and on the Rate of Sphincter-Sparing Surgery for Rectal Cancer：The Lyon R90-01 Randomized Trial［J］. J Clin Oncol，1999，17（8）：2396.
[26]
Hupkens BJP，Maas M，Martens MH，et al. Organ Preservation in Rectal Cancer After Chemoradiation：Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response？［J］. Ann Surg Oncol，2018，25（1）：197-203.
[27]
Terzi C，Bingul M，Arslan NC，et al. Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer［J］. Colorectal Dis，2020，22（3）：279-288.
[28]
Sloothaak DA，Geijsen DE，van Leersum NJ，et al. Optiamal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer［J］. Br J Surg，2013，100（7）：933-939.
[29]
中国直肠癌新辅助治疗后等待观察数据库研究协作组，中国医师协会外科医师分会中国医师协会肛肠医师分会，中华医学会外科学分会结直肠外科学组，等. 直肠癌新辅助治疗后等待观察策略专家共识（2020版）［J］. 中华胃肠外科杂志，2020，23（1）：1-9.
[30]
Nakagawa WT，Rossi BM，Ferreira FdO，et al. Chemoradiation instead of surgery to treat mid and low rectal tumors：Is it safe？［J］. Ann Surg Oncol，2002，9（6）：568-573.
[31]
Duldulao MP，Lee W，Streja L，et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer［J］. Dis Colon Rectum，2013，56（2）：142-149.
[32]
Habr-Gama A，Perez RO，Wynn G，et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer：characterization of clinical and endoscopic findings for standardization［J］. Dis Colon Rectum，2010，53（12）：1692-1698.
[33]
Smith JJ，Chow OS，Gollub MJ，et al. Organ Preservation in Rectal Adenocarcinoma：a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy，and total mesorectal excision or nonoperative management［J］. BMC Cancer，2015，15：767.
[34]
El Sissy C，Kirilovsky A，Van den Eynde M，et al. A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy［J］. Clin Cancer Res，2020，26（19）：5198-5207.
[35]
Zhou J，Wang C，Lin G，et al. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer：A Prospective Multicenter Study［J］. Clin Cancer Res，2021，27（1）：301-310.
[36]
Li ZW. ［Guiding significance of pathological diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy］［J］. Zhonghua Wei Chang Wai Ke Za Zhi，2020，23（3）：248-251.
[37]
Smith JJ，Strombom P，Chow OS，et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy［J］. JAMA Oncol，2019，5（4）：e185896.
[38]
Sao Juliao GP，Karagkounis G，Fernandez LM，et al. Conditional Survival in Patients With Rectal Cancer and Complete Clinical Response Managed by Watch and Wait After Chemoradiation：Recurrence Risk Over Time［J］. Ann Surg，2020，272（1）：138-144.
[39]
Smith FM，Cresswell K，Myint AS，et al. Is “watch-and-wait” after chemoradiotherapy safe in patients with rectal cancer？［J］. BMJ，2018，363：k4472.
[40]
Appelt AL，Pløen J，Harling H，et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer：a prospective observational study［J］. Lancet Oncol，2015，16（8）：919-927.
[41]
Aschele C，Cionini L，Lonardi S，et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer：pathologic results of the STAR-01 randomized phaseⅢtrial［J］. J Clin Oncol，2011，29（20）：2773-2780.
[42]
Gerard JP，Azria D，Gourgou-Bourgade S，et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer：results of the phaseⅢtrial ACCORD 12/0405-Prodige 2［J］. J Clin Oncol，2010，28（10）：1638-1644.
[43]
O'Connell MJ，Colangelo LH，Beart RW，et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer：surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04［J］. J Clin Oncol，2014，32（18）：1927-1934.
[44]
Rödel C，Graeven U，Fietkau R，et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer（the German CAO/ARO/AIO-04 study）：final results of the multicentre，open-label，randomised，phase 3 trial［J］. Lancet Oncol，2015，16（8）：979-989.
[45]
Deng Y，Chi P，Lan P，et al. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer：Initial Results of the Chinese FOWARC Multicenter，Open-Label，Randomized Three-Arm PhaseⅢTrial［J］. J Clin Oncol，2016，34（27）：3300-3307.
[46]
Habr-Gama A，Sao Juliao GP，Vailati BB，et al. Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer：Is It Really More Dangerous？［J］. Dis Colon Rectum，2019，62（6）：675-683.
[47]
Rullier E，Perez RO. Surgery or a watch-and-wait approach for rectal cancer？［J］. Lancet Oncol，2019，20（2）：189-190.
[48]
Minsky BD. Emerging trends in the treatment of rectal cancer［J］. Acta Oncol，2019，58（10）：1343-1351.
[49]
杨盈赤，杨鋆，张忠涛. 中国腹腔镜直肠癌手术30年回顾与展望［J/CD］. 中华普外科手术学杂志（电子版），2021，15（1）：6-9.
[1] 王振宁, 杨康, 王得晨, 邹敏, 归明彬, 王雅楠, 徐明. 机器人与腹腔镜手术联合经自然腔道取标本对中低位直肠癌患者远期疗效比较[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 437-442.
[2] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[3] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[4] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[5] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[6] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[7] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[8] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[9] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[10] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[12] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[13] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？